Explore the vast range of titles available.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com is being compensated up to six thousand dollars by a third party for a HWYI advertising and promotional services. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

Legal notice to investors: Certain matters discussed in this news release are \"forward-looking statements.\" These forward-looking statements, which apply only on the date of this release, generally can be identified by the use of forward-looking terminology such as \"may,\" \"will,\" \"expects,\" \"intends,\" \"estimates,\" \"anticipates,\" \"believes,\" \"continues\" or words of similar import. Similarly, statements that describe [Lev]'s future plans, objectives or goals are also forward-looking statements, which generally involve known and unknown risks, uncertainties and other facts that may cause the actual results, performance or achievements of Lev to be materially different from those expressed or implied by such forward-looking statements. Drug discovery and development involve a high degree of risk.

Lev Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev Pharmaceuticals' product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company is currently conducting a registrational Phase III clinical trial of its lead product candidate, C1-INH for the acute and prophylactic treatment of hereditary angioedema, a genetic disease affecting 6,000 or more people in the U.S. Lev is also evaluating the development of C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

LevPharma is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. LevPharma's product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The company's lead product candidate, C1-INH for the treatment of hereditary angioedema, is currently in a Phase III clinical trial in the U.S. LevPharma is also developing C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

Legal notice to investors: Certain matters discussed in this news release are \"forward-looking statements.\" These forward-looking statements, which apply only on the date of this release, generally can be identified by the use of forward-looking terminology such as \"may,\" \"will,\" \"expects,\" \"intends,\" \"estimates,\" \"anticipates,\" \"believes,\" \"continues\" or words of similar import. Similarly, statements that describe LevPharma's future plans, objectives or goals are also forward-looking statements, which generally involve known and unknown risks, uncertainties and other facts that may cause the actual results, performance or achievements of LevPharma to be materially different from those expressed or implied by such forward-looking statements.

LevPharma is developing its C1-INH product through an agreement with Sanquin Blood Supply Foundation (\"Sanquin\"), an Amsterdam-based not-for-profit organization that provides blood and plasma products and related services, carries out research and provides education, primarily in the Netherlands. Sanquin has been producing and selling successive generations of C1-INH, prepared from human plasma, in the Netherlands for over 30 years for the treatment of HAE. Continuous product development efforts at Sanquin have resulted in the current, highly purified product which has been marketed since 1997. Despite its long record of use in Europe, however, C1-INH, has never been introduced in the United States. Through a supply and distribution agreement with Sanquin, LevPharma has the exclusive right to market and sell C1-INH prepared by Sanquin for the treatment of HAE in North America and certain other geographic regions. LevPharma is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. LevPharma's product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. In addition to the treatment of hereditary angioedema, LevPharma is also developing C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

\"The net proceeds that we received will be used to complete our Phase III clinical trial for our lead product candidate, C1-INH for hereditary angioedema, and to advance our other development programs for C1-INH,\" continued Dr. [Joshua D. Schein, Ph.D.]. Based on its current cash balance and commitments, [Lev] believes that with the net proceeds received from this private placement, it should be able to maintain its current planned development activities and the corresponding level of expenditures through the launch of C1-INH for hereditary angioedema. No assurances, however, can be given that it will not need additional capital prior to such time. Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company initiated a Phase III clinical trial of its lead product candidate, C1-INH for the treatment of hereditary angioedema, in March 2005. In November 2005, we initiated a Phase III clinical trial of C1-INH for the prophylactic treatment of HAE. In October 2005, we received fast track designation status by the FDA for the treatment of HAE. Lev is also developing C1-INH for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

(BUSINESS WIRE)--Feb. 3, 2000--SIGA Pharmaceuticals, Inc. (NASDAQ: SGPH), today announced that as of February 1, 2000, the name of the company has been changed to SIGA Technologies, Inc. The Company further noted that its NASDAQ trading symbol will change to 'SIGA' effective Friday, February 4, 2000.

A very interesting indicator to look for is where the money is flowing into. We have a filter that we watch every morning that shows us \"Dollar Volume\". Here are a few of these stocks: Penn Traffic Company (OTC: PTFC), Lev Pharmaceuticals, Inc. (OTCBB: LEVP), Hathaway Corporation (OTC: HWYI), Narrowstep, Inc. (OTCBB: NRWS), and QSGI, Inc. (OTCBB: QSGI) Headquartered in Petersburg, Florida, Hathaway Corporation (OTC: HWYI) is engaged in the development and acquisition of undervalued companies as well as in providing communications and telecommunications software. Hathaway Corporation develops and acquires undervalued companies that bring a shift in how communications are delivered and serviced globally. Hathaway continues to seek out and capitalize on emerging technologies. Their first acquisition, OptiCon Systems, was first developed by Corning, a global 100 company. Corning spent millions of dollars and over seven years developing the Fiber Optic Management System currently marketed and sold by OptiCon Systems Inc. OptiCon serves over 70% of the global 500 companies such as Adelphia, Charter, Comcast, Comcast/ AT&T, Cox, Time Warner, and BrightHouse. Through Companies like OptiCon, Hathaway brings the communication solutions of the future to today's business marketplace. In the recent past, Hathaway has acquired OptiCon Systems Inc. and Diabetes. QSGI, INC. (OTCBB: QSGI) \"Up 11.61% at close on Thursday\" QSGI, INC. (OTCBB: QSGI), a technology services company, provides data security and compliance services, as well as data center hardware and data center maintenance services. Its data security and compliance services include data erasure for hard drives, environmental compliance for IT assets, remarketing for IT assets, and asset auditing/life cycle management. The company also resells used and refurbished computer products, including servers, laptop and desktop computers, monitors, PC processors, CD/DVD disk drives, modems, printers, and memory. QSGI's data center hardware services comprise reselling of refurbished mainframe processors, midrange processors, and associated peripheral products and connectivity products to companies worldwide. Further, QSGI offers hardware maintenance services for enterprise-class hardware, as well as data center consulting services to companies in the United States. The company offers its services for the users of business-computing hardware, such as desktops, laptops, related peripherals, and servers; and the users of enterprise-class hardware, such as mainframes, midrange processors, large storage, and controllers. QSGI was founded in 1967. It was formerly known as WindsorTech, Inc. and changed its name to QSGI, INC. in 2005. The company is based in Hightstown, New Jersey.